Member Info for schlemiel

The Sunday Times (The Tipster): Keep an eye on Seeing Machines.

D423

£71m mkt cap, £60m cash with the rest of the business (accumulated capex) thrown into the mix

thanks, appreciated

What will be NANO's net cash position when all Samsung obligations have been satisfied?

thanks

Well, the bid keeps strengthening

500k print

Joined yesterday...

Nano best position's it's been in here for years

T182

thanks mate

German govt to review the sale

No problem

COST is subject to stamp duty

Nm

Nm

It’s fair to say C4X Discovery had a fantastic start with the shares advancing 113 per cent over the foreshortened trading week after drug giant AstraZeneca delivered an $11million post-Christmas windfall.

It came in the form of what the experts call a ‘milestone payment’ under a $402million deal with Anglo-Swedish giant, which has licensed the right to NRF2 activator, created by C4XD to tackle chronic respiratory disease.

Analysts said the payment went further than adding a material sum to the AIM company’s coffers – it provided third-party validation of the technology.

'We see this as an important value inflexion which should reinvigorate sentiment in the share,' said regional broker Shore Capital.

'Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.'

https://www.thisismoney.co.uk/money/markets/article-12930315/SMALL-CAP-MOVERS-C4X-Discovery-cashes-deal-pharma-giant.html

Lombard is simply risk managing their investment after a decent rise...it's common amongst fund managers...

either way, the pharma sector's on the turn at last so bullishness is returning to a battered sector

Bought some...intriguing company

Lucy Tobin — hVIVO

Some bravery is needed to make a prediction for 2024, given the flurry of unforeseeable events we’ve been hit with so far this decade. But flu, asthma and malaria will certainly still be inflicted on us, so I’m backing hVIVO.

The Aim-listed firm runs fast-tracked human clinical trials — testing vaccines and antivirals by infecting volunteers in quarantine settings — for clients including Pfizer and GSK. It enjoyed a rollicking 2023, with its shares almost doubling, but there is more to come: this month, hVIVO signed a £17 million contract with Big Pharma to test a drug candidate for treating the respiratory virus RSV. In the coming months, it is also opening a 40,000 sq ft quarantine facility with 50 bedrooms in Canary Wharf; this should boost business further.

A pharmaceutical giant may well come knocking at chief executive Mo Khan’s door with a big cheque during 2024 — but even if not, hVIVO is a defensive, fast-growing stock to watch.

In a thinly traded market DMA players can feck around with the price, with impunity and without sanction

SOLG and Mather need to sell the whole shebang

Rk1 - cheers

Bought some at around 9p though been in and out of SOLG for yonks....Middlekoop seems pepped up and eyeing a corporate event of some sort

Broker upgrades are inevitable following Friday's news as this news indicates the direction of travel in terms of company strategy